SNBL USA appoints vp of business development

Mark Crane takes overall responsibility for marketing, sales and business development

SNBL USA, a provider of preclinical services, has announced the arrival of Mark Crane as vice president of business development.

Crane takes responsibility for the company’s marketing, sales and business development efforts. He joins SNBL USA from Ricerca Biosciences where he was vice president of global sales and marketing.

Crane has held similar positions at Bridge Pharmaceutical (formerly GeneLogic), Quest Pharmaceutical Services, and MDS Pharma Services.

SNBL USA is a subsidiary of Shin Nippon Biomedical Laboratories (SNBL), one of the largest CROs in Japan.

You may also like

Research & Development

PPD and SNBL form JV to provide clinical development services in Japan

Will combine PPD's clinical development operations in Japan with SNBL's clinical research division
Manufacturing

25 years of Guardtech: Isopod Manufacturing Director Michael Burton Q&A

One of the Group’s longest-serving superstars gives his thoughts on why the Guardtech Group are pushing the boundaries of small-scale cleanroom provision with their rapid-assembly pod systems
Research & Development

Genentech provides update on Astegolimab in chronic obstructive pulmonary disease

Pivotal Phase IIb ALIENTO study met the primary endpoint of a statistically significant reduction in the annualised exacerbation rate (AER) at 52 weeks when astegolimab was given every 2 weeks
Manufacturing

Aenova expands Killorglin site with spray drying platform

New equipment to help overcome bioavailability hurdles and accelerate time-to-market
Research & Development

Weight loss drugs such as Ozempic may prevent stroke and reduce brain injury related complications

Three studies presented at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether using GLP-1 inhibitors could lessen the impacts of stroke and related brain injuries or reduce the risk of stroke altogether
Research & Development

Amphista Therapeutics reaches research milestone and triggers a milestone payment from Merck

Collaboration focuses on the discovery of novel, non-CRBN/VHL, Targeted Glue degraders for oncology and immunology indications
Manufacturing

Precision under pressure

Why pharma manufacturing needs a harder look at weight control
Subscribe now